Table 1 Clinical characteristics of the study population
From: Long noncoding RNA dysregulation in ischemic heart failure
Characteristics | HF patients |
|---|---|
Age (years) (median ± SE) | 65.0 ± 0.6 |
Sex (male/female) | 17/1 |
Diabetics (%) | 28 |
BSA (m2) (median ± SE) | 1.8 ± 0.02 |
GFR (ml/min) (median ± SE) | 64.2 ± 1.6 |
Glucose (mg/dl) (median ± SE) | 105 ± 1.5 |
Time from MI (months) (median ± SE) | 5.5 ± 10.6 |
NYHA class (%) | 1 = 5; 2 = 55; 3 = 39; 4 = 1 |
DD (mm) (median ± SE) | 62.5 ± 0.5 |
SD (mm) (median ± SE) | 52.0 ± 0.5 |
LVEF (%) (median ± SE) | 26.5 ± 0.4 |
EDV (ml) (median ± SE) | 216.5 ± 2.7 |
ESV (ml) (median ± SE) | 151.0 ± 2.2 |
E/A (median ± SE) | 1.25 ± 0.1 |
Medications (%) | |
Oral antidiabetic agents | 15 |
Insulin | 20 |
Statins | 75 |
ACEIs | 70 |
β-Blockers | 80 |
Aspirin | 95 |
Loop diuretics | 85 |
Nitrates | 35 |